Gastrointestinal irAEs are more frequent and more severe in patients who receive CTLA-4 inhibitors than in those who receive PD-1 inhibitors, with rates of diarrhea ranging from 27% to 54% and colitis ranging from 8% to 22%. Here, PDCD1 is linked to colitis.